Literature DB >> 17290285

ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death.

M Schulte1, K Reiss, M Lettau, T Maretzky, A Ludwig, D Hartmann, B de Strooper, O Janssen, P Saftig.   

Abstract

The apoptosis-inducing Fas ligand (FasL) is a type II transmembrane protein that is involved in the downregulation of immune reactions by activation-induced cell death (AICD) as well as in T cell-mediated cytotoxicity. Proteolytic cleavage leads to the generation of membrane-bound N-terminal fragments and a soluble FasL (sFasL) ectodomain. sFasL can be detected in the serum of patients with dysregulated inflammatory diseases and is discussed to affect Fas-FasL-mediated apoptosis. Using pharmacological approaches in 293T cells, in vitro cleavage assays as well as loss and gain of function studies in murine embryonic fibroblasts (MEFs), we demonstrate that the disintegrin and metalloprotease ADAM10 is critically involved in the shedding of FasL. In primary human T cells, FasL shedding is significantly reduced after inhibition of ADAM10. The resulting elevated FasL surface expression is associated with increased killing capacity and an increase of T cells undergoing AICD. Overall, our findings suggest that ADAM10 represents an important molecular modulator of FasL-mediated cell death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290285     DOI: 10.1038/sj.cdd.4402101

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  68 in total

1.  Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-Aldrich syndrome protein.

Authors:  Nikolay P Nikolov; Masaki Shimizu; Sophia Cleland; Daniel Bailey; Joseph Aoki; Ted Strom; Pamela L Schwartzberg; Fabio Candotti; Richard M Siegel
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

2.  Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators.

Authors:  Gillian Murphy
Journal:  Int J Exp Pathol       Date:  2010-08       Impact factor: 1.925

Review 3.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

Review 4.  Fas death receptor signalling: roles of Bid and XIAP.

Authors:  T Kaufmann; A Strasser; P J Jost
Journal:  Cell Death Differ       Date:  2011-09-30       Impact factor: 15.828

5.  The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region.

Authors:  Raquel Herrero; Osamu Kajikawa; Gustavo Matute-Bello; Yi Wang; Naoki Hagimoto; Steve Mongovin; Venus Wong; David R Park; Nathan Brot; Jay W Heinecke; Henry Rosen; Richard B Goodman; Xiaoyun Fu; Thomas R Martin
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

6.  The emerging role of matrix metalloproteases of the ADAM family in male germ cell apoptosis.

Authors:  Ricardo D Moreno; Paulina Urriola-Muñoz; Raúl Lagos-Cabré
Journal:  Spermatogenesis       Date:  2011-07-01

7.  ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase.

Authors:  Thomas Tousseyn; Amantha Thathiah; Ellen Jorissen; Tim Raemaekers; Uwe Konietzko; Karina Reiss; Elke Maes; An Snellinx; Lutgarde Serneels; Omar Nyabi; Wim Annaert; Paul Saftig; Dieter Hartmann; Bart De Strooper
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

Review 8.  CD95, BIM and T cell homeostasis.

Authors:  Philippe Bouillet; Lorraine A O'Reilly
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

9.  Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.

Authors:  Liboria Siena; Elisabetta Pace; Maria Ferraro; Caterina Di Sano; Mario Melis; Mirella Profita; Mario Spatafora; Mark Gjomarkaj
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

10.  Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.

Authors:  José Sergio Zepeda-Nuño; Celia Guerrero-Velázquez; Susana Del Toro-Arreola; Natali Vega-Magaña; Julián Ángeles-Sánchez; Jesse Haramati; Ana L Pereira-Suárez; Miriam R Bueno-Topete
Journal:  Pathol Oncol Res       Date:  2016-09-14       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.